Irritable Bowel Syndrome: AGA Clinical Practice Guideline on the Pharmacological Management of Irritable Bowel Syndrome with Diarrhea (2022)

This guideline summary provides supportive information to patients and healthcare providers about the risks and benefits of pharmaceutical treatment decisions for irritable bowel syndrome (IBS) with a prevalence of diarrhea (IBS-D). The focus for this guideline and its eight recommendations include pharmaceuticals to treat IBS-D (eluxadoline, rifaximin, alosetron, and loperamide) as well as the three classes of pharmaceuticals used to manage IBS (tricyclic antidepressants (TCAs), selective serotonin reuptake inhibitors (SSRIs), and antispasmodics).
 

Download PDF Version